| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
CGEN
Compugen
|
May 21, 2026 | BUY |
Strong Buy
+148.2% avg upside
8 analysts
|
$5.00
134.83% Upside
|
· |
|
RCUS
Arcus Biosciences
|
Apr 20, 2026 | BUY |
Strong Buy
+14.6% avg upside
20 analysts
|
$47.00
62.41% Upside
|
+36.3% |
|
GILD
Gilead Sciences
|
Apr 07, 2026 | BUY |
Strong Buy
-6.5% avg upside
66 analysts
|
$129.00
2.44% Upside
|
-4.8% |
|
BNTX
BioNTech SE
|
Feb 02, 2026 | HOLD |
Strong Buy
+45.8% avg upside
26 analysts
|
$113.00
20.24% Upside
|
-16.2% |
|
MRK
Merck & Company
|
Dec 15, 2025 | BUY |
Strong Buy
+1.2% avg upside
43 analysts
|
$114.00
9.09% Downside
|
+26.9% |
|
IPSC
Century Therapeutics
|
Nov 17, 2025 | HOLD |
Strong Buy
+121.8% avg upside
11 analysts
|
$2.00
16.54% Downside
|
+410.4% |
|
SMMT
Summit Therapeutics
|
Oct 22, 2025 | SELL |
Strong Buy
+102.8% avg upside
27 analysts
|
— | +19.5% |
|
NBP
NovaBridge Biosciences
|
Oct 06, 2025 | BUY |
Strong Buy
+963.7% avg upside
14 analysts
|
$9.00
352.24% Upside
|
· |
|
IPHA
Innate Pharma
|
Sep 18, 2025 | HOLD |
Strong Buy
+256.0% avg upside
10 analysts
|
$2.00
8.48% Upside
|
+4.1% |
|
FATE
Fate Therapeutics
|
Sep 04, 2025 | BUY |
Buy
+301.5% avg upside
31 analysts
|
$7.00
132.27% Upside
|
+104.1% |
|
HOWL
Werewolf Therapeutics
|
Sep 04, 2025 | BUY |
Strong Buy
+1853.0% avg upside
8 analysts
|
$10.00
2728.01% Upside
|
-73.2% |
|
BOLT
Bolt Biotherapeutics
|
Sep 04, 2025 | HOLD |
Buy
+551.6% avg upside
7 analysts
|
$6.00
50.29% Upside
|
-17.2% |
|
XLO
Xilio Therapeutics
|
Aug 15, 2025 | BUY |
Strong Buy
+85.8% avg upside
7 analysts
|
$28.00
202.11% Upside
|
-6.6% |
|
ADAG
Adagene
|
Aug 13, 2025 | BUY |
Strong Buy
+64.8% avg upside
8 analysts
|
$7.00
47.41% Upside
|
+100.6% |
|
NKTX
Nkarta
|
Aug 13, 2025 | BUY |
Strong Buy
+555.0% avg upside
16 analysts
|
$8.00
181.14% Upside
|
+19.5% |
|
AFMDQ
Affimed
|
May 14, 2025 | HOLD |
Buy
+12648900.0% avg upside
15 analysts
|
$0.39
389900.08% Upside
|
· |
|
TIP
iShares TIPS Bond ETF
|
Nov 08, 2024 | BUY |
Strong Buy
1 analyst
|
— | +5.4% |
|
XOMA
XOMA Royalty Corporation
|
Sep 17, 2024 | BUY |
Buy
-47.4% avg upside
11 analysts
|
— | +28.5% |
|
MOLN
Molecular Partners
|
Aug 28, 2024 | HOLD |
Strong Buy
+154.5% avg upside
7 analysts
|
$6.00
52.60% Upside
|
-43.1% |
|
ASH
Ashland
|
Dec 11, 2023 | BUY |
Strong Buy
+10.1% avg upside
16 analysts
|
— | -7.8% |
|
NKTR
Nektar Therapeutics
|
Sep 15, 2023 | HOLD |
Buy
+8.8% avg upside
25 analysts
|
$1.50
97.59% Downside
|
+84.5% |
|
LINK
Interlink Electronics
|
Jun 05, 2023 | BUY |
Strong Buy
+117.0% avg upside
16 analysts
|
— | -28.8% |
|
GNCAQ
Genocea Biosciences
|
Apr 27, 2022 | BUY |
Strong Buy
+332333233.3% avg upside
10 analysts
|
$5.00
249999899.91% Upside
|
· |
|
SPRY
ARS Pharmaceuticals
|
Apr 01, 2022 | HOLD |
Strong Buy
+168.9% avg upside
12 analysts
|
$1.80
77.28% Downside
|
+102.8% |
|
CH:MOLN
Molecular Partners AG
|
Apr 06, 2021 | BUY |
Strong Buy
+567.1% avg upside
5 analysts
|
$35.00
1029.01% Upside
|
· |
|
DE:MRK
Merck KGaA
|
Aug 25, 2020 | BUY |
Buy
-6.8% avg upside
33 analysts
|
$87.82
39.27% Downside
|
· |
|
FBRX
Forte Biosciences
|
May 22, 2019 | HOLD |
Strong Buy
+91.5% avg upside
14 analysts
|
$5.00
76.49% Downside
|
-72.3% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.